You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
CareDx and Invitae each had massive share-price gains last month. Exact Sciences, GenMark, and Natera also saw sizeable increases in their stock prices.
The company also said it launched a new comprehensive diagnostic called HeartCare for surveillance of heart transplant patients.
The firm said momentum from the launch of its kidney transplant test Allosure drove the overall revenue increase.
CareDx has paid Illumina a $5 million initial payment and will pay royalties in the mid-single to low-double digits on sales of future commercialized products.
A brief recap of Diagnostics news the week of Apr 20, 2018: Boston Scientific, Interpace, Human Longevity, CareDX, OpGen SeraCare Life Sciences, Omega Diagnostics, MDxHealth's SelectMDx.
The firm says its Olerup QType test is available on both Roche and Applied Biosystems platforms.
Interpace Diagnostics Group announced this week that it has entered into an agreement with Acupath Laboratories through which Acupath will sell Interpace's ThyGenX and ThyraMIR tests.
The company said it had a large uptick in testing revenues during the quarter, including for its AlloSure kidney transplant test, which was launched in October.
Perceptive Credit Holdings has agreed to provide the company with the loan, which CareDx said it will use to repay outstanding debt.
The firm said it expects fourth quarter revenues of $12.3 million to $12.5 million, a year-over-year increase of 13 percent to 15 percent.